Citi Boosts Eli Lilly with Buy Rating, Eyes Growth
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
- Latest
- Trending
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
Explore how U.S. states are leading AI regulation efforts, focusing on industry-specific and high-risk AI systems.
Whales shift focus to Intel Markets after debate, as ETH, DOGE prices dip.
United Airlines to offer free Starlink Wi-Fi on over 1,000 aircraft by 2025, enhancing passenger connectivity.
U.S. plans to curb low-value Chinese imports, affecting e-commerce giants like JD.com, Alibaba, and Pinduoduo.
New US tariffs on Chinese imports, including EVs, solar cells, and semiconductors, aim to shift supply chains from China.
WebPT and Intel partner on AI motion capture for physical therapy, integrating RealSense technology into EMR for enhanced patient care.
XRP and DOGE outperform as Bitcoin dips. Market sees drop in large transactions, indicating cautious big players.
The U.S. Commerce Department's AI proposal could increase compliance costs and shift the global AI landscape.
Bitcoin miners sell $1.71B in 3 days. Can BTC maintain above $60,000 or is the rally fading?
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.